Author

Bart A. Ploeger

Observed names: B A Ploeger, B PLOEGER, B Ploeger, B. A. Ploeger, B. PLOEGER, B. Ploeger, B.A. Ploeger, Bart A Ploeger, Bart Ploeger, Bart A. Ploeger, Ploeger, B.

Institution: Bayer (Germany)

Observed institutions: Leiden University, Novartis (Switzerland), Institute of Cancer Research, Bayer (United States), Utrecht University, Tel Aviv Sourasky Medical Center, Leiden University Medical Center, Helsinki University Hospital, Rambam Health Care Campus, Weston Park Cancer Centre, Royal Marsden Hospital, AstraZeneca (Sweden), Novartis Institutes for BioMedical Research, Organon (Netherlands), Bayer (Germany)

ORCID: 0000-0003-1183-7458

Observed ORCID: 0000-0003-1183-7458

OpenAlex ID: A5017280045

Mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling in translational drug research

2008 · M DANHOF, E DELANGE, et al. · Trends in Pharmacological Sciences · 290

Mechanism-Based Pharmacokinetic-Pharmacodynamic Modeling: Biophase Distribution, Receptor Theory, and Dynamical Systems Analysis

2006 · Meindert Danhof, Joost de Jongh, et al. · The Annual Review of Pharmacology and Toxicology · 259

Extensions to the Visual Predictive Check to facilitate model performance evaluation

2008 · Teun M. Post, Jan I. Freijer, et al. · Journal of Pharmacokinetics and Pharmacodynamics · 214

PDF

The Pharmacokinetics of Glycyrrhizic Acid Evaluated by Physiologically Based Pharmacokinetic Modeling†

2001 · Bart Ploeger, Tjeert Mensinga, et al. · Drug Metabolism Reviews · 204

Clinical Trial Simulation: A Review

2010 · N Holford, S C Ma, et al. · Clinical Pharmacology & Therapeutics · 199

A Mechanism-based Disease Progression Model for Comparison of Long-term Effects of Pioglitazone, Metformin and Gliclazide on Disease Processes Underlying Type 2 Diabetes Mellitus

2006 · Willem de Winter, Joost DeJongh, et al. · Journal of Pharmacokinetics and Pharmacodynamics · 148

Explaining Variability in Tacrolimus Pharmacokinetics to Optimize Early Exposure in Adult Kidney Transplant Recipients

2009 · Rogier R Press, Bart A Ploeger, et al. · Therapeutic Drug Monitoring · 143

Discovery of AZD3839, a Potent and Selective BACE1 Inhibitor Clinical Candidate for the Treatment of Alzheimer Disease

2012 · Fredrik Jeppsson, Susanna Eketjäll, et al. · Journal of Biological Chemistry · 138

PDF

Physiologically Based Pharmacokinetic Modeling to Investigate Regional Brain Distribution Kinetics in Rats

2012 · Joost Westerhout, Bart Ploeger, et al. · The AAPS Journal · 125

PDF

Regorafenib plus nivolumab in patients with mismatch repair-proficient/microsatellite stable metastatic colorectal cancer: a single-arm, open-label, multicentre phase 2 study

2023 · Marwan Fakih, Kanwal Pratap Singh Raghav, et al. · EClinicalMedicine · 124

PDF

Mitotane has a strong and a durable inducing effect on CYP3A4 activity

2011 · Nielka P van Erp, Henk-Jan Guchelaar, et al. · European Journal of Endocrinology · 119

Evaluation of Clinically Relevant Drug–Drug Interactions and Population Pharmacokinetics of Darolutamide in Patients with Nonmetastatic Castration-Resistant Prostate Cancer: Results of Pre-Specified and Post Hoc Analyses of the Phase III ARAMIS Trial

2019 · Neal Shore, Christian Zurth, et al. · Targeted Oncology · 103

PDF

Incorporating Receptor Theory in Mechanism-Based Pharmacokinetic-Pharmacodynamic (PK-PD) Modeling

2009 · Bart A. Ploeger, Piet H. van der Graaf, et al. · Drug Metabolism and Pharmacokinetics · 78

Estimation of Systemic Toxicity of Acrylamide by Integration of in Vitro Toxicity Data with Kinetic Simulations

1999 · J. DeJongh, M. Nordin-Andersson, et al. · Toxicology and Applied Pharmacology · 75

Systemic and Direct Nose-to-Brain Transport Pharmacokinetic Model for Remoxipride after Intravenous and Intranasal Administration

2011 · Jasper Stevens, Bart A. Ploeger, et al. · Drug Metabolism and Disposition · 65

Physiologically Based Pharmacokinetic Modeling of Glycyrrhizic Acid, a Compound Subject to Presystemic Metabolism and Enterohepatic Cycling

2000 · Bart A. Ploeger, Jan Meulenbelt, et al. · Toxicology and Applied Pharmacology · 54

Marginal increase of sunitinib exposure by grapefruit juice

2010 · Nielka P. van Erp, Sharyn D. Baker, et al. · Cancer Chemotherapy and Pharmacology · 53

PDF

Pharmacokinetic-Pharmacodynamic Model for the Reversal of Neuromuscular Blockade by Sugammadex

2008 · Bart A. Ploeger, Jean Smeets, et al. · Anesthesiology · 50

NT‐proBNP Qualifies as a Surrogate for Clinical End Points in Heart Failure

2021 · Walter Schmitt, Hauke Rühs, et al. · Clinical Pharmacology & Therapeutics · 48

PDF

Mechanism-based PK–PD model for the prolactin biological system response following an acute dopamine inhibition challenge: quantitative extrapolation to humans

2012 · Jasper Stevens, Bart A. Ploeger, et al. · Journal of Pharmacokinetics and Pharmacodynamics · 47

Changes in GABAA receptor properties in amygdala kindled animals: In vivo studies using [11C]flumazenil and positron emission tomography

2008 · Lia C. Liefaard, Bart A. Ploeger, et al. · Epilepsia · 44

PDF

A Human Physiologically-Based Model for Glycyrrhzic Acid, A Compound Subject to Presystemic Metabolism and Enterohepatic Cycling

2000 · Bart Ploeger, Tjeert Mensinga, et al. · Pharmaceutical Research · 44

The virtue of translational PKPD modeling in drug discovery: selecting the right clinical candidate while sparing animal lives

2013 · Tjerk Bueters, Bart A. Ploeger, et al. · Drug Discovery Today · 43

Population pharmacokinetic characterization of BAY 81‐8973, a full‐length recombinant factor VIII : lessons learned ‒ importance of including samples with factor VIII levels below the quantitation limit

2017 · D. Garmann, S. McLeay, et al. · Haemophilia · 40

PDF

Explaining variability in ciclosporin exposure in adult kidney transplant recipients

2010 · Rogier R. Press, Bart A. Ploeger, et al. · European Journal of Clinical Pharmacology · 36

PDF

Works count: 122

Citation count: 3,292

H-index: 29

I10-index: 45